Annals of Hematology

Papers
(The H4-Index of Annals of Hematology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning75
A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration53
Correction to: Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders51
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate51
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease49
Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia49
Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia49
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma49
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib43
T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults36
“In situ” MYC rearrangement and amplification as a secondary change in a case of High-grade B cell lymphoma with 11q aberration35
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments34
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma32
Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature31
Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia29
Absence of blood donors’ anti-SARS-CoV-2 antibodies in pre-storage leukoreduced red blood cell units indicates no role of passive immunity for blood recipients28
Advances in the ocular complications after hematopoietic stem cell transplantation28
Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials26
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data24
Optimizing hemophagocytic lymphohistiocytosis screening in children: validation of the HLH-Screen score23
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study23
Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome23
Second allogeneic transplantation in relapsed acute leukemia – a risk worth taking?23
Germline mutations predispose a concurrent thymoma and diffuse large B-cell lymphoma23
0.10753607749939